

Peter Ochodnický

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10770005/publications.pdf>

Version: 2024-02-01

22
papers

758
citations

566801

15
h-index

752256

20
g-index

22
all docs

22
docs citations

22
times ranked

1396
citing authors

#	ARTICLE	IF	CITATIONS
1	Î²-Cyclodextrin counteracts obesity in Western diet-fed mice but elicits a nephrotoxic effect. Scientific Reports, 2019, 9, 17633.	1.6	9
2	Excessive dietary lipid intake provokes an acquired form of lysosomal lipid storage disease in the kidney. Journal of Pathology, 2018, 246, 470-484.	2.1	32
3	Metabolic injury-induced NLRP3 inflammasome activation dampens phospholipid degradation. Scientific Reports, 2017, 7, 2861.	1.6	30
4	High glucose induces HGF-independent activation of Met receptor in human renal tubular epithelium. Journal of Receptor and Signal Transduction Research, 2017, 37, 535-542.	1.3	17
5	Increased Circulating and Urinary Levels of Soluble TAM Receptors in Diabetic Nephropathy. American Journal of Pathology, 2017, 187, 1971-1983.	1.9	16
6	Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats. American Journal of Physiology - Renal Physiology, 2016, 310, F1047-F1053.	1.3	5
7	Perinatally administered losartan augments renal <sc>ACE</sc>2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. Journal of Cellular and Molecular Medicine, 2015, 19, 1965-1974.	1.6	96
8	Pioglitazone, a PPARÎ³ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat. European Journal of Pharmacology, 2014, 730, 51-60.	1.7	17
9	Bradykinin modulates spontaneous nerve growth factor production and stretch-induced ATP release in human urothelium. Pharmacological Research, 2013, 70, 147-154.	3.1	25
10	Specificity evaluation of antibodies against human Î²3-adrenoceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385, 875-882.	1.4	35
11	Neurotrophins as regulators of urinary bladder function. Nature Reviews Urology, 2012, 9, 628-637.	1.9	78
12	Expression profiling of Gâ€proteinâ€coupled receptors in human urothelium and related cell lines. BJU International, 2012, 110, E293-300.	1.3	34
13	Î²-Adrenoceptor agonist effects in experimental models of bladder dysfunction. , 2011, 131, 40-49.		29
14	Desirable properties of Î²3-adrenoceptor agonists: Implications for the selection of drug development candidates. European Journal of Pharmacology, 2011, 657, 1-3.	1.7	10
15	Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourology and Urodynamics, 2011, 30, 1227-1241.	0.8	115
16	Mechanisms of nerve growth factor release from a human urothelial cell line. FASEB Journal, 2011, 25, 1020.5.	0.2	0
17	Tissue functions mediated by Î²3-adrenoceptorsâ€™ findings and challenges. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 103-108.	1.4	39
18	Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. American Journal of Physiology - Renal Physiology, 2010, 298, F625-F633.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Gene expression profiling of G-protein coupled receptors in human urothelial cell lines. FASEB Journal, 2010, 24, 773-13.	0.2	1
20	Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. Nephrology Dialysis Transplantation, 2008, 24, 413-420.	0.4	9
21	Microalbuminuria and Endothelial Dysfunction: Emerging Targets for Primary Prevention of End-organ Damage. Journal of Cardiovascular Pharmacology, 2006, 47, S151-S162.	0.8	95
22	Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. Journal of Nephrology, 2006, 19, 246-58.	0.9	37